Literature DB >> 18480287

Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice.

Feng Xu1, Michael P Vitek, Carol A Colton, Mary Lou Previti, Nastaran Gharkholonarehe, Judianne Davis, William E Van Nostrand.   

Abstract

Human apolipoprotein (ApoE) genotype influences the development of Alzheimer's disease and cerebral amyloid angiopathy (CAA). Specific mutations within the amyloid-beta protein (Abeta) peptide have been identified that cause familial forms of CAA. However, the effect of APOE genotype on accumulation of CAA mutant Abeta in brain is not well understood. In the present study, we determined how human ApoE3 or ApoE4 influence cerebral Abeta accumulation in transgenic mice (Tg-SwDI) that accumulate human Dutch/Iowa (E22Q/D23N) CAA mutant Abeta in brain, primarily in the form of fibrillar cerebral microvascular amyloid. Using Tg-SwDI mice bred onto a human APOE3/3 or human APOE4/4 background, we found that both human ApoE3 and ApoE4 proteins led to a strong reduction in the amount of cerebral microvascular amyloid with an unexpected concomitant appearance of extensive fibrillar parenchymal plaque amyloid. There was strong colocalization of all ApoE proteins with fibrillar amyloid deposits in the mice. In Tg-SwDI/hAPOE3/3 and Tg-SwDI/hAPOE4/4 mice, there was no change in the levels of total Abeta(40) and Abeta(42) or in the amounts of soluble and insoluble Abeta in brain compared with Tg-SwDI mice on the endogenous mouse APOE background. The shift from primarily cerebral microvascular amyloid to parenchymal plaque amyloid in Tg-SwDI/hAPOE3/3 and Tg-SwDI/hAPOE4/4 mice resulted in a parallel shift in the association of activated microglia. These findings indicate that human ApoE has a strong influence on the spatial development of human Dutch/Iowa CAA mutant amyloid accumulation in mouse brain and that microglial activation is in response to the spatial accumulation of fibrillar amyloid.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18480287      PMCID: PMC2657728          DOI: 10.1523/JNEUROSCI.1042-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  39 in total

Review 1.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

2.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease.

Authors:  K R Bales; T Verina; D J Cummins; Y Du; R C Dodel; J Saura; C E Fishman; C A DeLong; P Piccardo; V Petegnief; B Ghetti; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

3.  Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy.

Authors:  T J Grabowski; H S Cho; J P Vonsattel; G W Rebeck; S M Greenberg
Journal:  Ann Neurol       Date:  2001-06       Impact factor: 10.422

Review 4.  Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy.

Authors:  D M Holtzman
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 5.  Relationship between severe amyloid angiopathy, apolipoprotein E genotype, and vascular lesions in Alzheimer's disease.

Authors:  J M Olichney; L A Hansen; J H Lee; C R Hofstetter; R Katzman; L J Thal
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

6.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.

Authors:  Ronald B DeMattos; Mark A O'dell; Maia Parsadanian; Jennie W Taylor; Judith A K Harmony; Kelly R Bales; Steven M Paul; Bruce J Aronow; David M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-26       Impact factor: 11.205

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

8.  APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein.

Authors:  K Chalmers; G K Wilcock; S Love
Journal:  Neuropathol Appl Neurobiol       Date:  2003-06       Impact factor: 8.090

Review 9.  Alzheimer disease and cerebrovascular pathology: an update.

Authors:  K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2002-05       Impact factor: 3.575

10.  Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice.

Authors:  Yong Ji; Bruno Permanne; Einar M. Sigurdsson; David. M. Holtzman; Thomas Wisniewski
Journal:  J Alzheimers Dis       Date:  2001-02       Impact factor: 4.472

View more
  11 in total

Review 1.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

Review 2.  Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease.

Authors:  C Dirk Keene; Eiron Cudaback; Xianwu Li; Kathleen S Montine; Thomas J Montine
Journal:  Curr Opin Neurobiol       Date:  2011-09-08       Impact factor: 6.627

Review 3.  Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy.

Authors:  Vitaly Vasilevko; Giselle F Passos; Daniel Quiring; Elizabeth Head; Richard C Kim; Mark Fisher; David H Cribbs
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

4.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.

Authors:  Rashid Deane; Abhay Sagare; Katie Hamm; Margaret Parisi; Steven Lane; Mary Beth Finn; David M Holtzman; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2008-11-13       Impact factor: 14.808

5.  Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease.

Authors:  Yair M Gozal; Duc M Duong; Marla Gearing; Dongmei Cheng; John J Hanfelt; Christopher Funderburk; Junmin Peng; James J Lah; Allan I Levey
Journal:  J Proteome Res       Date:  2009-11       Impact factor: 4.466

Review 6.  Role of vascular risk factors and vascular dysfunction in Alzheimer's disease.

Authors:  Dara L Dickstein; Jessica Walsh; Hannah Brautigam; Steven D Stockton; Samuel Gandy; Patrick R Hof
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

7.  APOE-ε2 and APOE-ε4 correlate with increased amyloid accumulation in cerebral vasculature.

Authors:  Peter T Nelson; Nina M Pious; Gregory A Jicha; Donna M Wilcock; David W Fardo; Steven Estus; G William Rebeck
Journal:  J Neuropathol Exp Neurol       Date:  2013-07       Impact factor: 3.148

8.  Distinct brain regional proteome changes in the rTg-DI rat model of cerebral amyloid angiopathy.

Authors:  Joseph M Schrader; Feng Xu; William E Van Nostrand
Journal:  J Neurochem       Date:  2021-08-17       Impact factor: 5.546

9.  Impact of age on the cerebrovascular proteomes of wild-type and Tg-SwDI mice.

Authors:  James L Searcy; Thierry Le Bihan; Natalia Salvadores; James McCulloch; Karen Horsburgh
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

10.  Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models.

Authors:  Fan Liao; Tony J Zhang; Hong Jiang; Katheryn B Lefton; Grace O Robinson; Robert Vassar; Patrick M Sullivan; David M Holtzman
Journal:  Acta Neuropathol Commun       Date:  2015-11-10       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.